Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

Living with ET: Monitoring and Long-Term Health

At a Glance

Living with Essential Thrombocythemia (ET) requires long-term monitoring of blood counts and controlling cardiovascular risks to prevent blood clots. While the risk of ET progressing to more aggressive blood cancers is low, patients must stay vigilant for red flags like weight loss or night sweats.

Living with Essential Thrombocythemia (ET) is a marathon, not a sprint. Because ET is a chronic condition, the focus of your care will inevitably shift from the shock of the initial diagnosis to long-term survivorship and monitoring [1]. This means learning to live alongside the uncertainty of a rare disease while actively managing the health factors that are firmly within your control [2][3].

Long-Term Monitoring

A standard monitoring schedule for ET typically involves regular blood tests, called a Complete Blood Count (CBC). While intervals vary depending on your risk level and whether your counts are stable, these routine checkups allow your doctor to track broad trends rather than obsessing over individual numbers [4][5].

Managing “Lab Anxiety”

It is very common for patients to experience intense anxiety before their scheduled blood work—sometimes called “scanxiety” or “lab anxiety.” Remembering that ET is a slow-moving condition can help ground you. Your doctor isn’t looking for a “perfect” number on a given day; they are looking for stability over months and years [6][4].

Understanding Progression Risks

One of the most common and terrifying fears for ET patients is the risk of the disease changing into something more aggressive, such as post-ET myelofibrosis or Acute Myeloid Leukemia (AML).

  • The Numbers: The cumulative risk of these transformations is relatively low—approximately 9% over a 15-year period [7].
  • The Context: Patients who were correctly diagnosed with “true” ET (and not pre-fibrotic myelofibrosis in disguise) have the lowest rates of progression [8][9].

Red Flags for Transformation

While your doctor will monitor your routine labs, you should report any of the following “red flags” immediately, as they may trigger a repeat bone marrow biopsy to aggressively check for disease evolution [10][5]:

  • Unexplained Weight Loss: Losing significant weight without trying [11].
  • Drenching Night Sweats: Sweats so severe that they require you to change your pajamas or sheets [11].
  • New Anemia: A sudden drop in your hemoglobin or red blood cell count [12][11].
  • Splenomegaly: A new or worsening feeling of fullness or pain in the upper left side of your abdomen (under the ribs) [12][13].
  • Rising LDH: A sharp increase in lactate dehydrogenase (LDH), a blood marker of cell turnover [13][14].

Controlling the Controllables

While you cannot control the genetic mutations driving your ET, you have massive power over your cardiovascular risk factors. These lifestyle factors can be just as important as your platelet count in determining your long-term health and survival [2][15].

  • Blood Pressure and Lipids: High blood pressure (hypertension) and high cholesterol (hyperlipidemia) significantly increase the risk of the very blood clots that ET treatment aims to prevent [2][3]. Working closely with a primary care doctor to keep these strictly in a healthy range is a critical part of ET care [16][17].
  • Smoking: Smoking is one of the single greatest avoidable risks for ET patients, as it rapidly damages blood vessels and exponentially increases the likelihood of a major thrombotic event [2][3].
  • Active Lifestyle: Regular, moderate exercise helps maintain vascular health and can drastically improve the fatigue often associated with MPNs [18][19].

The Road Ahead

Your journey with ET is entirely unique. By staying informed, reporting new symptoms promptly, and meticulously managing your overall heart health, you can take an active, empowering role in your survivorship [20][21]. The goal is to ensure that ET remains a manageable part of your life, not the defining feature of it.

Common questions in this guide

What are the signs that essential thrombocythemia is progressing?
Red flags for ET progression include unexplained weight loss, drenching night sweats, a sudden drop in red blood cells, or a feeling of fullness in your upper left abdomen. If you notice any of these symptoms, contact your hematologist immediately.
Will my essential thrombocythemia turn into leukemia or myelofibrosis?
The overall risk of ET transforming into a more aggressive condition like post-ET myelofibrosis or acute myeloid leukemia is relatively low. Studies show the cumulative risk is approximately 9% over a 15-year period for patients with true ET.
How often do I need blood tests if I have ET?
Routine monitoring typically involves regular Complete Blood Count (CBC) tests. The exact schedule depends on your individual risk level and how stable your blood counts have been over time, as doctors look for long-term trends rather than daily fluctuations.
What lifestyle changes can help manage essential thrombocythemia?
Controlling cardiovascular risk factors is critical for ET patients. Managing blood pressure and cholesterol, quitting smoking, and maintaining an active lifestyle can significantly lower your risk of life-threatening blood clots.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How have my blood counts and LDH levels trended over the last year, rather than just looking at today's numbers?
  2. 2.What is my personal goal for blood pressure and cholesterol management to help critically lower my risk of clots?
  3. 3.Are my current 'mild' symptoms, such as fatigue or a feeling of fullness in my abdomen, significant enough to warrant a repeat bone marrow biopsy?
  4. 4.What specific changes in my lab work or physical symptoms would immediately trigger a repeat bone marrow biopsy?
  5. 5.Can we schedule a dedicated consultation to discuss the long-term emotional impact of monitoring and how I can better manage 'scanxiety'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.

    Accurso V, Santoro M, Mancuso S, et al.

    Clinical medicine insights. Blood disorders 2020; (13()):2634853520978210 doi:10.1177/2634853520978210.

    PMID: 33447121
  2. 2

    Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival.

    Accurso V, Santoro M, Mancuso S, et al.

    Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020008 doi:10.4084/MJHID.2020.008.

    PMID: 31934318
  3. 3

    Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.

    Sobieralski P, Bieniaszewska M, Bołkun Ł, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2025; (34(1)):25-32 doi:10.17219/acem/182857.

    PMID: 38683044
  4. 4

    Essential thrombocythemia: challenges in clinical practice and future prospects.

    Godfrey AL, Green AC, Harrison CN

    Blood 2023; (141(16)):1943-1953 doi:10.1182/blood.2022017625.

    PMID: 36379024
  5. 5

    Current challenges in the management of essential thrombocythemia.

    Kleman A, Singavi AK, Michaelis LC

    Clinical advances in hematology & oncology : H&O 2017; (15(10)):773-783.

    PMID: 29040257
  6. 6

    Contemporary approach to essential thrombocythemia and polycythemia vera.

    Aruch D, Mascarenhas J

    Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

    PMID: 26717193
  7. 7

    Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.

    Chuzi S, Stein BL

    Leukemia & lymphoma 2017; (58(12)):2786-2798 doi:10.1080/10428194.2017.1312371.

    PMID: 28503969
  8. 8

    Advances and challenges in the management of essential thrombocythemia.

    Birgegård G

    Therapeutic advances in hematology 2015; (6(3)):142-56 doi:10.1177/2040620715580068.

    PMID: 26137205
  9. 9

    Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

    Gisslinger H, Jeryczynski G, Gisslinger B, et al.

    Leukemia 2016; (30(5)):1126-32 doi:10.1038/leu.2015.360.

    PMID: 26710883
  10. 10

    Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

    Courtier F, Garnier S, Carbuccia N, et al.

    Genes, chromosomes & cancer 2020; (59(1)):30-39 doi:10.1002/gcc.22789.

    PMID: 31340059
  11. 11

    Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis.

    Iwaki K, Ueda Y, Mishima M, et al.

    Clinical journal of gastroenterology 2021; (14(1)):293-296 doi:10.1007/s12328-020-01274-6.

    PMID: 33136259
  12. 12

    Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

    PMID: 27870387
  13. 13

    Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review.

    Nahmod KA, Miranda RN, Vega F, et al.

    Leukemia & lymphoma 2025; (66(4)):764-772 doi:10.1080/10428194.2024.2422846.

    PMID: 39704386
  14. 14

    Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

    Maekawa T, Kato S, Kawamura T, et al.

    Blood 2019; (134(10)):814-825 doi:10.1182/blood.2019000051.

    PMID: 31270105
  15. 15

    Excess mortality in younger patients with myeloproliferative neoplasms.

    Abu-Zeinah K, Saadeh K, Silver RT, et al.

    Leukemia & lymphoma 2023; (64(3)):725-729 doi:10.1080/10428194.2022.2070914.

    PMID: 35532314
  16. 16

    Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia.

    Furuya C, Hashimoto Y, Morishita S, et al.

    Journal of thrombosis and thrombolysis 2023; (55(2)):263-272 doi:10.1007/s11239-022-02751-0.

    PMID: 36484956
  17. 17

    Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.

    Pósfai É, Marton I, Borbényi Z, Nemes A

    Anatolian journal of cardiology 2016; (16(6)):397-402 doi:10.14744/AnatolJCardiol.2015.6125.

    PMID: 27182615
  18. 18

    Massive Anterior STEMI Due to Essential Thrombocythemia Leading to Urgent Thrombocytapheresis.

    Rioux AV, Morin L, Bernier M, et al.

    JACC. Case reports 2025; (30(37)):105731 doi:10.1016/j.jaccas.2025.105731.

    PMID: 41123536
  19. 19

    From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

    Stein BL, Martin K

    Blood 2019; (134(22)):1902-1911 doi:10.1182/blood.2019001318.

    PMID: 31778549
  20. 20

    From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

    Stein BL, Martin K

    Hematology. American Society of Hematology. Education Program 2019; (2019(1)):397-406 doi:10.1182/hematology.2019001318.

    PMID: 31808903
  21. 21

    Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

    Zulkeflee RH, Zulkafli Z, Johan MF, et al.

    International journal of environmental research and public health 2021; (18(14)) doi:10.3390/ijerph18147582.

    PMID: 34300032

This page provides educational information about living with and monitoring Essential Thrombocythemia (ET). Always consult your hematologist regarding your specific lab results, symptom changes, and cardiovascular risks.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.